Armed with HIF‐1α downregulation by Tanespimycin, TISN reversed the immunosuppressive tumor microenvironment and ultimately achieved a superior inhibition in both local and abscopal tumors by this synergistic mitochondria‐targeted PIT strategy.57 The gene discussed is HIF1A; the disease is neoplasm.